Innate Pharma

Innate Pharma Net Income

The Net Income of Innate Pharma (IPH.PA) as of Nov 4, 2026 is -49.18 M EUR. In the previous year, Net Income was -49.47 M EUR — a change of -0.59% (higher).

Net Income

-49.18 MEUR

YoY

-0.59%

Last updated:

In 2025, Innate Pharma's profit amounted to -49.18 M EUR, a -0.59% increase from the -49.47 M EUR profit recorded in the previous year.

The Innate Pharma Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2023
-7.57 M EUR
Jan 1, 2024
-49.47 M EUR
Jan 1, 2025
-49.18 M EUR
Jan 1, 2026 (e)
-11.92 M EUR
Jan 1, 2027 (e)
-10.21 M EUR
Jan 1, 2028 (e)
48.63 M EUR
Jan 1, 2029 (e)
21.07 M EUR
Jan 1, 2030 (e)
42.96 M EUR
The Innate Pharma Net Income history
YEARNet IncomeYoY
est42.96 MEUR+103.85%
est21.07 MEUR-56.67%
est48.63 MEUR-576.19%
est-10.21 MEUR-14.32%
est-11.92 MEUR-75.76%
-49.18 MEUR-0.59%
-49.47 MEUR+553.51%
-7.57 MEUR-86.97%
-58.10 MEUR+10.02%
-52.81 MEUR-17.47%
-63.98 MEUR+208.22%
-20.76 MEUR-780.85%
3.05 MEUR-106.30%
-48.39 MEUR-482.79%
12.64 MEUR-288.49%
-6.71 MEUR-65.87%
-19.65 MEUR+579.36%
-2.89 MEUR-9.60%
-3.20 MEUR-54.17%
-6.98 MEUR-48.89%
-13.66 MEUR-6.62%
-14.63 MEUR+48.46%
-9.85 MEUR+10.47%
-8.92 MEUR+47.60%
-6.04 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innate Pharma Revenue

Innate Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
51.90 M EUR
-12.67 M EUR
-7.57 M EUR
Jan 1, 2024
12.62 M EUR
-51.58 M EUR
-49.47 M EUR
Jan 1, 2025
2.79 M EUR
-57.36 M EUR
-49.18 M EUR
Jan 1, 2026 (e)
49.38 M EUR
-10.99 M EUR
-11.92 M EUR
Jan 1, 2027 (e)
71.68 M EUR
-11.09 M EUR
-10.21 M EUR
Jan 1, 2028 (e)
134.46 M EUR
84.99 M EUR
48.63 M EUR
Jan 1, 2029 (e)
99.87 M EUR
32.01 M EUR
21.07 M EUR
Jan 1, 2030 (e)
146.34 M EUR
62.56 M EUR
42.96 M EUR

Innate Pharma Margins

Innate Pharma stock margins

The Innate Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innate Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innate Pharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
10.83 %
-24.41 %
-14.59 %
Jan 1, 2024
-252.41 %
-408.61 %
-391.94 %
Jan 1, 2025
100.00 %
-2,058.02 %
-1,764.51 %
Jan 1, 2026 (e)
100.00 %
-22.26 %
-24.14 %
Jan 1, 2027 (e)
100.00 %
-15.48 %
-14.25 %
Jan 1, 2028 (e)
100.00 %
63.21 %
36.17 %
Jan 1, 2029 (e)
100.00 %
32.05 %
21.10 %
Jan 1, 2030 (e)
100.00 %
42.75 %
29.35 %

Innate Pharma Stock analysis

What does Innate Pharma do? The company Innate Pharma SA is a biotechnology company that was founded in 1999 by immunologist Hervé Brailly. The company is headquartered in Marseille, France, and currently employs approximately 200 people. The business model of Innate Pharma is based on the research and development of immunotherapeutic drugs for various types of cancer and infectious diseases. The company leverages its expertise in the research and utilization of the so-called "innate immune system," which refers to the body's natural defense mechanisms against pathogens and cancer cells. Innate Pharma is active in various business sectors focusing on the development and marketing of therapeutic agents and products. These include: - Oncology: In the field of oncology, the company focuses on the development of drugs that specifically target cancer cells and inhibit cancer growth. Innate Pharma particularly emphasizes the research of antibodies that bind specifically to cancer cells and destroy them. An important product in this area is the medication Lumoxiti, used for the treatment of hairy cell leukemia. - Infectious diseases: In addition to cancer research, Innate Pharma also dedicates itself to the development of therapeutic agents against various infectious diseases. A significant focus here is on viral infections such as COVID-19. The company collaborates closely with various partners and research institutions to identify and develop promising agents. - Autoimmune diseases: Another business sector of Innate Pharma is the research and development of therapies for autoimmune diseases. The company primarily focuses on the use of antibodies and other proteins that aim to selectively influence the immune system and prevent misguided reactions of the body. Innate Pharma has developed and launched a variety of products in recent years. These primarily include therapeutic antibodies that specifically target various structures in the body and activate the body's immune defenses. An important product in this area is the monoclonal antibody IPH4102, used for the treatment of T-cell lymphoma. Innate Pharma collaborates closely with various partners and research institutions to identify and develop promising agents. These include large pharmaceutical companies such as Roche and Bristol-Myers Squibb, as well as innovative start-ups and university hospitals. The close collaboration with the research community aims to ensure that Innate Pharma remains at the forefront of progress and can quickly implement new developments. Like many biotechnology companies, research and development at Innate Pharma are very costly. To finance the development of new therapies, the company relies on cooperation with investors and the issuance of shares. In 2019, Innate Pharma generated a revenue of approximately 47 million euros and incurred a loss of about 55 million euros. However, the company is optimistic about achieving further successes in the coming years and expanding its position as a leading biotechnology company. Innate Pharma is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Innate Pharma's Profit Margins

The profit margins of Innate Pharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Innate Pharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Innate Pharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Innate Pharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Innate Pharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Innate Pharma stock

Net Income of Innate Pharma is -49.18 M EUR in 2025.

Net Income of Innate Pharma changed from -49.47 M EUR to -49.18 M EUR, representing a -0.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Income Innate Pharma since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Innate Pharma historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Innate Pharma

All Key Metrics — Innate Pharma